FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma
Authors
Keywords
-
Journal
International Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-20
DOI
10.1007/s10147-020-01696-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC
- (2019) Fengrui Zhou et al. Aging-US
- FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer
- (2017) S Chen et al. Oncogenesis
- Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities
- (2016) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
- (2016) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
- (2016) Masaki Shimoji et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
- (2016) Yufan Yang et al. Oncotarget
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
- (2014) Shenyou Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human Cancer
- (2014) Rocky Cipriano et al. MOLECULAR CANCER RESEARCH
- A rapid nested polymerase chain reaction method to detect circulating cancer cells in breast cancer patients using multiple marker genes
- (2014) LEI LIU et al. Oncology Letters
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
- (2012) Sun-Young Lee et al. JOURNAL OF CLINICAL INVESTIGATION
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Detection of circulating cancer cells in lung cancer patients with a panel of marker genes
- (2008) Lei Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started